{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:32:50Z","timestamp":1789914770671,"version":"4.0.1"},"reference-count":43,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":8586,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1994,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The widespread use of benzodiazepines has led to increasing recognition of their unwanted effects. The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In London and Toronto 154 patients who met DSM\u2013III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo. Subjects in each drug group also received either exposure or relaxation. Treatment was from weeks 0 to 8 and was then tapered from weeks 8 to 16.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean alprazolam dose was 5 mg daily. Compared with placebo subjects, alprazolam patients developed more adverse reactions (21 % v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia. Side-effects tended to diminish during treatment but remained significant at week 8. Despite this, the drop-out rate was low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Alprazolam caused side-effects and adverse effects during treatment but many patients were willing to accept these.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1192\/bjp.165.1.79","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T01:26:25Z","timestamp":1224033985000},"page":"79-86","source":"Crossref","is-referenced-by-count":35,"title":["Safety and Side-effects of Alprazolam Controlled Study in Agoraphobia with Panic Disorder"],"prefix":"10.1192","volume":"165","author":[{"given":"G. H.","family":"O'Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Noshirvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Basoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Swinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000072238_ref6","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1192\/bjp.164.5.652","article-title":"Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse","volume":"164","author":"Baso$gblu","year":"1994","journal-title":"British Journal of Psychiatry"},{"key":"S0007125000072238_ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290027004"},{"key":"S0007125000072238_ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"S0007125000072238_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90630-2"},{"key":"S0007125000072238_ref27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1176\/ajp.144.2.254b","article-title":"Sexual side effects of alprazolam","volume":"144","author":"Lydiard","year":"1987","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000072238_ref24","unstructured":"Lader M. (1985) Achieving treatment goals: limitations of therapies. Internal Medicine for the Specialist (special issue), 29."},{"key":"S0007125000072238_ref32","doi-asserted-by":"publisher","DOI":"10.1207\/s15327043hup0103_1"},{"key":"S0007125000072238_ref20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"S0007125000072238_ref36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1176\/ajp.141.6.792","article-title":"Emergence of hostility during alprazolam treatment","volume":"141","author":"Rosenbaum","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000072238_ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6424.1135"},{"key":"S0007125000072238_ref28","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.162.6.776"},{"key":"S0007125000072238_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-197105000-00008"},{"key":"S0007125000072238_ref26","first-page":"343","article-title":"SAFTEE: a technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000072238_ref7","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198019030-00004"},{"key":"S0007125000072238_ref23","first-page":"309","volume-title":"Benzodiazepines Divided","author":"Lader","year":"1983"},{"key":"S0007125000072238_ref22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/ajp.133.1.82","article-title":"Thioridazine and sexual dysfunction","volume":"133","author":"Kotin","year":"1976","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000072238_ref12","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.160.1.135a"},{"key":"S0007125000072238_ref34","doi-asserted-by":"publisher","DOI":"10.1177\/070674378503000808"},{"key":"S0007125000072238_ref35","first-page":"167","article-title":"Comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder","volume":"22","author":"Rizley","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000072238_ref11","doi-asserted-by":"publisher","DOI":"10.1007\/BF00464571"},{"key":"S0007125000072238_ref37","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1176\/ajp.142.10.1223a","article-title":"Inhibited female orgasm as a side effect of alprazolam","volume":"142","author":"Sangal","year":"1985","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000072238_ref39","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198310000-00001"},{"key":"S0007125000072238_ref30","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.151.1.107"},{"key":"S0007125000072238_ref42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1176\/ajp.145.4.531","article-title":"Sexual dysfunction related to alprazolam treatment of social phobia","volume":"145","author":"Uhde","year":"1988","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000072238_ref29","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198602000-00028"},{"key":"S0007125000072238_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92524-6"},{"key":"S0007125000072238_ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1985.01790280055005"},{"key":"S0007125000072238_ref31","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290037005"},{"key":"S0007125000072238_ref13","first-page":"458","article-title":"Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study","volume":"47","author":"Dunner","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000072238_ref14","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198122060-00005"},{"key":"S0007125000072238_ref16","doi-asserted-by":"publisher","DOI":"10.1007\/BF00422410"},{"key":"S0007125000072238_ref1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1980"},{"key":"S0007125000072238_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(84)90248-X"},{"key":"S0007125000072238_ref21","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.121.6.610"},{"key":"S0007125000072238_ref5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1185\/03007998409109541","article-title":"A cross-national comparison of anti-anxiety\/sedative drug use","volume":"8","author":"Balter","year":"1984","journal-title":"Current Medical Research and Opinion"},{"key":"S0007125000072238_ref2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0773.1985.tb01305.x","article-title":"Psychomotor effects of alprazolam and diazepam during acute and subacute treatment and during followup phase","volume":"56","author":"Aranko","year":"1985","journal-title":"Acta Pharmacologica Toxicologica"},{"key":"S0007125000072238_ref43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1176\/ajp.144.1.25","article-title":"Diazepam-induced amnesia","volume":"144","author":"Wolkowitz","year":"1987","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000072238_ref17","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-349-03642-4_30"},{"key":"S0007125000072238_ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb04801.x"},{"key":"S0007125000072238_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90198-7"},{"key":"S0007125000072238_ref40","first-page":"22","article-title":"Effects of minor tranquillizers and antidepressants on psychomotor performance","volume":"48","author":"Smiley","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000072238_ref38","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-1176-8"},{"key":"S0007125000072238_ref41","volume-title":"Structured Clinical Interview for DSM\u2013III, Upjohn Version (SCID-UP).","author":"Spitzer","year":"1983"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000072238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T14:22:18Z","timestamp":1738419738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000072238\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1994,7]]}},"alternative-id":["S0007125000072238"],"URL":"https:\/\/doi.org\/10.1192\/bjp.165.1.79","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,7]]}}}